CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

Opinion
Video

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

The discussion focuses on newer data with B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy in later lines of therapy for relapsed/refractory multiple myeloma, demonstrating median progression-free survival over 2 years, which is unprecedented in this setting. Combinations of CAR T-cell therapy with other novel agents like bispecific antibodies are planned to further improve the depth and durability of response.

However, higher-grade cytokine release syndrome and neurotoxicity remains an issue with CAR T-cell therapy vs bispecific antibodies. Careful patient selection and disease debulking prior to cell infusion is important to mitigate toxicity. Additional therapy soon after CAR T-cell therapy may improve sustained responses, but optimal bridging therapy and sequencing requires further study given concerns over T-cell exhaustion or exacerbating cytopenias.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
Francesco Di Meo, PhD
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Video 8 - "Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression"
Video 7 - "The Importance of Thyroidectomy in DTC Patient Care"
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Hans Lee, MD, associate professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Michael J. Overman, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer